Tentt

Aurinia to Acquire Kezar for $6.955/Share

Announced
HealthcareMerger

Deal Overview

Aurinia Pharmaceuticals has agreed to acquire Kezar Life Sciences in a merger transaction. The consideration is $6.955 in cash per share plus a contingent value right.

The deal is announced and structured as a strategic acquisition in the healthcare sector, with Aurinia as the buyer and Kezar Life Sciences as the target.

Key Details

Transaction
Aurinia Pharmaceuticals acquires Kezar Life Sciences
Deal Size
Under $10M
Reported Value
$6.955 in Cash per Share plus a Contingent Value Right

Filed under

Source

Read full article on businesswire.com

via GN - site:businesswire.com · March 30, 2026

Powered by Tentt

Source healthcare deals for your firm

Tentt builds and operates managed deal origination services for PE firms, M&A advisors, and commercial lenders. We map the target universe, monitor signals, and execute outreach — white-labelled to your firm.

Book a 30-min intro call

Related Deals

See all Healthcare deals →